FDA lifts restrictions on Medtronic's diabetes business

The agency also approved the Minnesota med-tech company's latest insulin pump.

April 26, 2023 at 11:00AM
Medtronic, which has its operational headquarters in Fridley, had received a warning from the Food and Drug Administration detailing concerns about some of its insulin pumps. (Glen Stubbe, Star Tribune file/The Minnesota Star Tribune)

The U.S. Food and Drug Administration says Medtronic's diabetes business is back in compliance.

The agency issued a warning letter in December 2021 that detailed concerns about how Medtronic handled recalls and complaints over some of its insulin pumps.

However, Medtronic said late Tuesday all regulatory restrictions associated with the letter are resolved.

The news came after the agency on Friday approved Medtronic's MiniMed 780G insulin pump. The warning letter — and related restrictions — delayed approval for Medtronic diabetes devices. The FDA recently re-inspected Medtronic's facility in Northridge, Calif., where the diabetes business is based.

"We're very thankful to the agency for working with us so collaboratively," said Que Dallara, president of Medtronic Diabetes, in a statement.

Diabetes is Medtronic's smallest business line. It accounted for $2.3 billion of revenue for the company's fiscal 2022, or 7.4% of the company's overall sales. However, Medtronic CEO Geoff Martha is bullish about the diabetes business in the long term.

about the writer

Burl Gilyard

Medtronic/medtech reporter

Burl Gilyard is the Star Tribune's medtech reporter.

See More

More from Business

Light and dark arrows pointing in opposite directions over a file photo of white and black school children in the 1950s.

Minnesota's schools will need to desegregate, more housing will need to be built and even basic assumptions about one another have to change.

card image